In early 2022, researchers at the University of Colorado Anschutz Medical Campus observed an unexpected connection between viral infections and cancer recurrence in laboratory mice. Their study, focused on mice with dormant breast cancer cells, found that infection with either influenza or SARS-CoV-2 significantly increased the likelihood of developing aggressive metastatic lung tumors. While findings in animal models do not always translate directly to humans, subsequent analysis of human healthcare data revealed similar patterns.

Data from the U.K. Biobank indicated that cancer survivors who contracted COVID-19 in 2020—prior to the availability of vaccines—had a higher risk of dying from recurring cancer within a year compared to those who did not contract the virus. Additionally, a separate U.S. database examining breast cancer patients in remission showed a greater incidence of metastatic lung tumors among those infected with COVID-19.

Researchers noted limitations in analyzing the impact of influenza, mainly due to underreporting of flu infections in medical records, as many patients experience mild illness managed at home. The severity of COVID-19 infection and its role in cancer recurrence could not be definitively assessed due to data constraints.

While the studies have not established COVID-19 as an oncogenic virus—unlike known cancer-causing viruses such as human papillomavirus or hepatitis B and C—some scientists suggest that viral infections like COVID-19 and influenza may reactivate dormant cancer cells. These cells are typically controlled by the immune system but could become active during or after viral infection due to inflammatory responses.

A key focus has been the role of cytokines, immune signaling proteins released during infection. In severe viral cases, excessive cytokine production, known as a cytokine storm, can occur. Elevated levels of interleukin-6 (IL-6), a cytokine implicated in both severe COVID-19 and cancer processes, have been linked to cancer metastasis and recurrence. University of Colorado researchers demonstrated that breast cancer cells in mice reactivated following viral infection corresponded with increased IL-6 levels.

However, the precise biological mechanisms remain under debate. Some scientists propose that IL-6-induced suppression of mitochondrial function—the cell's energy generators—may facilitate cancer recurrence. This concept aligns with broader research on mitochondrial dysfunction in both long COVID and cancer progression.

Experts caution that the current evidence does not definitively prove a causal relationship between COVID-19 and cancer recurrence. The observations are considered preliminary, with the need for further investigation emphasized. Some researchers remain skeptical, calling for more robust data before drawing conclusions.

In the interim, medical professionals stress the importance of preventive measures, particularly for individuals with compromised immune systems or chronic illnesses. Vaccination and avoiding severe infection from COVID-19, influenza, and other respiratory viruses are regarded as prudent strategies to reduce potential risks associated with viral inflammation and possible cancer recurrence.

As ongoing research continues to explore the long-term effects of COVID-19, the connection between viral infections and cancer relapse represents an area of growing scientific interest and clinical concern.